Pancreatic Cancer

In this video, Kim A. Reiss, MD, discussed the results of a randomized phase 1b/2 study of niraparib plus nivolumab or ipilimumab in patients with advanced pancreatic cancer, which were presented in a poster session at ASCO2022.

In this video, Timothy Brown, MD, discussed the results of his study on treatment outcomes of patients with platinum-sensitive BRCA or PALB2-mutated pancreatic cancer who have been treated with and progressed on rucaparib.

In this video, Robert Vonderheide, MD, DPhil, discussed the results of the phase 2 randomized study of chemoimmunotherapy for patients with metastatic pancreatic cancer.

CHICAGO — Potentially targetable oncogenic rearrangements are more prevalent among patients with KRAS wild-type pancreatic cancer than those with KRAS-mutated disease, according to study results presented at ASCO Annual Meeting.

CHICAGO — The addition of nimotuzumab to gemcitabine prolonged OS and PFS among patients with KRAS wild-type locally advanced or metastatic pancreatic cancer, according to randomized phase 3 study results presented at ASCO Annual Meeting.

A woman with metastatic pancreatic cancer attained a 72% partial response with T-cell receptor gene therapy, according to a report published in The New England Journal of Medicine.

A presenter at Digestive Disease Week reported that gallstone disease may be a predictor of pancreatic cancer.

Patients with pancreatic ductal adenocarcinoma were six times more likely to have had cholelithiasis or cholecystitis in the year before diagnosis compared with the general population, according to data presented at Digestive Disease Week.

Neoadjuvant gemcitabine-based chemoradiotherapy prolonged OS compared with upfront surgery among patients with resectable and borderline resectable pancreatic cancer, according to phase 3 study results in Journal of Clinical Oncology.

Limaca Medical announced it has received breakthrough device designation from the FDA for its Precision-GI endoscopic ultrasound biopsy device, according to a company press release.